slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
189,721-189,780 of 319,975
18
Includes a timeline of biopsy (Bx) and treatment, and paired dot plots showing pre/post treatment changes in CD68+ and CD3+ cell counts.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
19
Spider plot (swimmer plot variant) showing individual patient tumor response trajectories.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
20
The slide uses a two-part structure: a value proposition box followed by a list of upcoming milestones.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
21
Apexigen | Investor Presentation Deck | 27 slidesApexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
22
The slide uses a biological process diagram to illustrate the mechanism of action.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
23
Includes statistical significance markers (*, **, ***) and TGI (Tumor Growth Inhibition) percentages.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
24
Apexigen | Investor Presentation Deck | 27 slidesApexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
25
The slide uses a three-pillar structure supported by a foundational platform.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
26
The slide uses a Gantt-style timeline to map clinical trial events (P2 data, FDA meetings, enrollment) against a calendar axis from 2021 to 2023.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
27
Apexigen | Investor Presentation Deck | 27 slidesApexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
01
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations 1 hit
02
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations 1 hit
03
Comparison of Tmax metrics and safety profiles for single vs repeat dosing.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
04
The slide uses callout boxes connected to specific organs to detail symptom frequency and clinical manifestations.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Agitate (Make it worse)1 hit
05
The chart uses a dual-line comparison to show the divergence in risk outcomes based on treatment timing.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
07
Includes box plot showing 10th/90th percentiles and line chart showing concentration over 20 minutes.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
08
Box plot showing baseline adjusted epinephrine Tmax.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
09
Shows rapid onset of therapeutic benefits for AQST-109.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
10
Clinical trial data comparing sublingual/oral film (AQST-109) vs intramuscular injection.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
11
The chart shows box plots for baseline adjusted Epinephrine Cmax, highlighting differences in drug exposure between the two treatment groups.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
12
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
13
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
14
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations 1 hit
01
Includes company logo, ticker symbol, and a representative photo of a patient.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
02
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
03
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
04
The slide uses academic citations to establish the clinical relevance of the target protein.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
Includes a scientific diagram of the signaling pathway and references to academic literature.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
Includes a bifurcation diagram illustrating the relationship between SNAIL and ZEB mRNA levels in different cell phenotypes.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
07
The slide uses a visual comparison of biological mechanisms to argue for the superiority of the company's 'Decoy AXL Receptor' approach.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
08
The slide uses a two-column layout to contrast the drug's engineering/profile with its biomarker/IP strategy.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
09
The slide uses a standard organizational structure layout with headshots and a logo grid for credibility.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a horizontal bar chart format to represent clinical trial stages for different drug combinations.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
11
The pie chart visualizes the relative size of the patient populations described in the list.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
13
The slide uses a process flow diagram to show the Phase 1b study arms.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
14
Includes specific clinical metrics (ORR, mPFS, mOS) comparing patients above and below the Minimal Efficacious Concentration (MEC).Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
15
The slide includes two scatter plots with error bars and two summary tables of experimental data.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
16
The slide uses a swimmer plot (left) and a waterfall plot (right) to visualize clinical response.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
17
The slide highlights clinical efficacy data from a Phase 1b trial (PROC).Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
18
The slide compares clinical outcomes (ORR, SD, CBR, PD) across four cohorts: two treatment groups and two historical control groups.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
19
Includes trial design diagram with randomization and endpoint hierarchy.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
20
The slide uses qualitative feedback from healthcare providers and KOLs to validate market demand.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
21
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
22
The slide uses a process flow diagram to illustrate the trial structure.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
23
The slide includes detailed footnotes explaining specific adverse events and patient outcomes.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
24
Includes footnotes comparing results to historical METEOR and CANTATA studies.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
25
Data compares low vs high biomarker groups across different dosage cohorts.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
26
The slide outlines a clinical trial protocol including randomization, interim analysis for accelerated approval, and primary/secondary endpoints.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
27
The slide uses a table to summarize key value propositions and speech bubbles to provide direct KOL validation.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
28
The slide features a photo of a patient being comforted, emphasizing the human element of the medical treatment.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
29
The slide outlines a standard clinical trial schema with a dose-finding/safety phase followed by a randomized efficacy phase.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
30
Data cutoff date is August 18, 2022. N=21 patients.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
31
Includes a footnote comparing results to a historical P3 study.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
32
Swimmer plot showing patient IDs on y-axis and weeks on study on x-axis, with various clinical status markers.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
33
Data shows a clear correlation between achieving MEC and better clinical outcomes in PDAC patients.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
34
PDAC stands for Pancreatic Ductal Adenocarcinoma. RP2D stands for Recommended Phase 2 Dose.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
35
Includes qualitative feedback from KOLs and healthcare providers regarding clinical utility and patient selection.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
36
The slide uses a horizontal timeline with four distinct time periods, each containing multiple clinical trial or regulatory events.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit